Compare places
Two or three clusters, read side by side across sectors, research, companies, capital, infrastructure, government designations and UKIZ relevance. There is no score and no ranking: British clusters are different from one another, not better or worse than one another.
Choose up to three clusters
- London
- Cambridge
- Oxford
- Manchester
- Birmingham & the West Midlands
- Bristol & Bath
- Sheffield & Rotherham
- Leeds & West Yorkshire
- Liverpool City Region
- Newcastle & the North East
- Teesside & the Humber
- Edinburgh
- Glasgow & the Central Belt
- Belfast
- Cardiff & South Wales
- Southampton & Portsmouth
- Cornwall & Plymouth
- Nottingham & Derby
- Norwich & the East
Side by side
| Dimension | CambridgeEast of England | OxfordSouth East | Leeds & West YorkshireYorkshire and the Humber |
|---|---|---|---|
| Sectors | Life Sciences, Semiconductors, Engineering Biology, Artificial Intelligence Supporting: Quantum Technologies, Advanced Materials, AgriTech & FoodTech, Digital Technologies | Quantum Technologies, Life Sciences, Space, Artificial Intelligence Supporting: Clean Energy, Advanced Materials, Engineering Biology | Life Sciences, Digital Technologies, Financial Technology Supporting: Artificial Intelligence, Advanced Manufacturing, Creative Industries |
| Research |
|
|
|
| Companies |
| Not recorded on the map. |
|
| Infrastructure |
University and institute laboratories, genomics and biomedical campus facilities, and semiconductor design capability. |
National laboratory campus facilities, quantum fabrication and metrology capability, and clinical research infrastructure. | Not recorded on the map. Health data infrastructure, teaching hospitals and university research facilities. |
| Capital | Specialist deep tech and life science funds, university-linked funds, and corporate partners; strong at seed, thinner at growth stage relative to demand. | University-linked funds and specialist deep tech investors, with London capital an hour away. | Financial services depth locally, but early-stage health technology capital remains limited. |
| Government programmes | No place-based designation recorded. | No place-based designation recorded. | No place-based designation recorded. |
| What exists | Extreme research density for its size: life sciences and genomics, semiconductor and processor IP, engineering biology and AI, with a mature spin-out culture and specialist investors who understand long timelines. | A research-intensive university alongside the Harwell campus, one of the largest concentrations of national scientific infrastructure in Britain, spanning space, energy, health and physical sciences, with distinctive quantum, vaccine and space applications strength. | National health data organisations, medical technology, a large financial and professional services base and a research university with data and materials strength. |
| What's missing · UKIZ interpretation | Ownership retention. Discovery and early company formation work; the Series B onward stage frequently transfers ownership overseas. Laboratory and scale-up space, power and housing also constrain growth. | Access. National facilities are heavily used by their own communities; companies without an existing university relationship find the route in unclear. Scale-up space and later-stage capital are also constrained. | A clear route for companies to work with health data at scale, and clinical adoption pathways that move faster than pilot projects. |
| What could connect · UKIZ interpretation | Cambridge discovery connected to UK manufacturing and biomanufacturing capacity, and to later-stage domestic capital, so that value created here is realised here rather than acquired out of the country. | Opening national facility access to companies across Britain as shared ecosystem infrastructure, and pairing Oxford quantum and space capability with manufacturing clusters that could produce at volume. | Leeds health data capability connected to Manchester clinical research and to medical technology manufacturing, giving companies discovery, evidence and production in one region. |
| UKIZ relevance | Cambridge produces intellectual property at a rate few places match, and loses ownership of too much of it at Series B. The proposed Oxford–Cambridge zone concentrates on commercialisation and retention rather than on more discovery. | Oxford has infrastructure most countries cannot build. The proposed zone focuses on making that infrastructure accessible to companies that are not spin-outs of the university. | Health data at population scale is a national asset. The proposed Manchester mission and Leeds capability are complementary rather than competing. |
| Last verified | 15 August 2026 | 15 August 2026 | 15 August 2026 |
Proposed by UKIZ · not a government designation